Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Report Points To A Flexible, Functioning Market

Executive Summary

The British Generic Manufacturers Association has commissioned a detailed report that points to a functioning, flexible market with low prices but that remains attractive to industry, and which is quick to respond to price spikes.

You may also be interested in...



BGMA’s Smith Reflects On 25 Years Of Progress

As Warwick Smith steps down after 25 years as leader of the British Generic Manufacturers Association, he talks about how far the country’s off-patent industry has come over the last quarter-century – including the acceptance of generics, the advent of biosimilars, and how freedom of pricing has helped to keep costs low while maintaining sustainable pricing – in the first part of an exclusive interview with Generics Bulletin.

UK Industry Is Puzzled By State-Ownership Proposal

Plans unveiled by the UK’s main opposition party to set up a publicly-owned generics manufacturer fail to recognize the benefits and savings created through multisource competition, the country’s generics industry believes.

IGBA And WHO Highlight Korean Training Hub

Following the announcement in February that South Korea had been chosen by the WHO as the location for a global biomanufacturing training hub, a video shared by the IGBA has shed more light on what can be expected from the initiative.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel